Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Parra

Showing results (281-290 of 292) with videos related to

Pageof 30
Sort By:
Nature|March 19, 2024
Author Correction: An atlas of epithelial cell states and plasticity in lung adenocarcinomaGuangchun Han, Ansam Sinjab, Zahraa Rahal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2021
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancerL Federico, D J McGrail, S-E Bentebibel, et al.
Cancer Discovery|May 11, 2021
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell SequencingAnsam Sinjab, Guangchun Han, Warapen Treekitkarnmongkol, et al.
Journal of the National Cancer Institute|September 15, 2021
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung AdenocarcinomasIchidai Tanaka, Delphine Dayde, Mei Chee Tai, et al.
BMC Infectious Diseases|June 27, 2022
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical studyManuel Rojas, Yhojan Rodríguez, Juan Carlos Hernández, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature Communications|November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Pageof 30

Showing results (281-290 of 292) with videos related to

Sort By:
Pageof 30
Nature|March 19, 2024
Author Correction: An atlas of epithelial cell states and plasticity in lung adenocarcinomaGuangchun Han, Ansam Sinjab, Zahraa Rahal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2021
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancerL Federico, D J McGrail, S-E Bentebibel, et al.
Cancer Discovery|May 11, 2021
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell SequencingAnsam Sinjab, Guangchun Han, Warapen Treekitkarnmongkol, et al.
Journal of the National Cancer Institute|September 15, 2021
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung AdenocarcinomasIchidai Tanaka, Delphine Dayde, Mei Chee Tai, et al.
BMC Infectious Diseases|June 27, 2022
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical studyManuel Rojas, Yhojan Rodríguez, Juan Carlos Hernández, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Nature Communications|November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Pageof 30